Skip to main content
Top
Published in: International Journal of Hematology 5/2020

01-11-2020 | Primary Myelofibrosis | Original Article

Prevalence and risk factors of high echocardiographic probability of pulmonary hypertension in myeloproliferative neoplasms patients

Authors: Yanika Jindamai, Ekarat Rattarittamrong, Arintaya Phrommintikul, Lalita Yongsmith, Pokpong Piriyakhuntorn, Thanawat Rattanathammethee, Sasinee Hantrakool, Chatree Chai-Adisaksopha, Adisak Tantiworawit, Lalita Norasetthada

Published in: International Journal of Hematology | Issue 5/2020

Login to get access

Abstract

Pulmonary hypertension (PH) is emerging as a complication of myeloproliferative neoplasms (MPNs). This was a prospective study conducted at Chiang Mai University Hospital. The primary objective was to determine the prevalence of high echocardiographic probability of PH in MPNs patients. The secondary objectives were to determine risk factors of PH and the correlation between risk factors and peak tricuspid regurgitation velocity (TRVmax). All MPNs patients aged over 18 years, including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), were enrolled. All eligible patients underwent echocardiography for evaluation of the probability of PH in line with the 2015 European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Guidelines. Sixty-six patients with a median age of 59 years were enrolled. There were 35 PV, 25 ET, and 6 PMF patients included. The prevalence of high echocardiographic probability of PH was 4.55% (2 ET and 1 PMF). Risk factors associated with high echocardiographic probability of PHT were not analyzed. There were three risk factors associated with increased TRVmax, specifically lower hemoglobin, older age, and the presence of JAK2V617F mutation. The prevalence of high echocardiographic probability of PH in MPNs patients was 4.55%.
Appendix
Available only for authorised users
Literature
1.
go back to reference Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67–119.CrossRef Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67–119.CrossRef
2.
go back to reference Simonneau G, Gatzoulis M, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D34–41.CrossRef Simonneau G, Gatzoulis M, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D34–41.CrossRef
3.
go back to reference Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.CrossRef Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.CrossRef
4.
go back to reference Yaylali YT, Yilmaz S, Akgun-Cagliyan G, Kilic O, Kaya E, Senol H, et al. Association of disease subtype and duration with echocardiographic evidence of pulmonary hypertension in myeloproliferative neoplasm. Med Princ Pract. 2020. (Epub ahead of print) Yaylali YT, Yilmaz S, Akgun-Cagliyan G, Kilic O, Kaya E, Senol H, et al. Association of disease subtype and duration with echocardiographic evidence of pulmonary hypertension in myeloproliferative neoplasm. Med Princ Pract. 2020. (Epub ahead of print)
5.
go back to reference McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53:1573–619.CrossRef McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53:1573–619.CrossRef
6.
go back to reference Dingli D, Utz JP, Krowka MJ, Oberg AL, Tefferi A. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest. 2001;120:801–8.CrossRef Dingli D, Utz JP, Krowka MJ, Oberg AL, Tefferi A. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest. 2001;120:801–8.CrossRef
7.
go back to reference Gupta R, Perumandla S, Patsiornik Y, Niranjan S, Ohri A. Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders. J Natl Med. 2006;98:1779–822. Gupta R, Perumandla S, Patsiornik Y, Niranjan S, Ohri A. Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders. J Natl Med. 2006;98:1779–822.
8.
go back to reference Garypidou V, Vakalopoulou S, Dimitriadis D, Tziomalos K, Sfikas G, Perifanis V. Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders. Haematologica. 2004;89:245–7.PubMed Garypidou V, Vakalopoulou S, Dimitriadis D, Tziomalos K, Sfikas G, Perifanis V. Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders. Haematologica. 2004;89:245–7.PubMed
9.
go back to reference Lopez-Mattei J, Verstovsek S, Fellman B, Iliescu C, Bhatti K, Hassan SA, et al. Prevalence of pulmonary hypertension in myelofibrosis. Ann Hematol. 2019;99:781–9.CrossRef Lopez-Mattei J, Verstovsek S, Fellman B, Iliescu C, Bhatti K, Hassan SA, et al. Prevalence of pulmonary hypertension in myelofibrosis. Ann Hematol. 2019;99:781–9.CrossRef
10.
go back to reference Austin M, Quesenberry PJ, Ventetuolo CE, Liang O, Reagan JL. Prevalence and effect on survival of pulmonary hypertension in myelofibrosis. Clin Lymphoma Myeloma Leuk. 2019;19:593–7.CrossRef Austin M, Quesenberry PJ, Ventetuolo CE, Liang O, Reagan JL. Prevalence and effect on survival of pulmonary hypertension in myelofibrosis. Clin Lymphoma Myeloma Leuk. 2019;19:593–7.CrossRef
11.
go back to reference Venton G, Turcanu M, Colle J, Thuny F, Chebrek S, Farnault L, et al. Pulmonary hypertension in patients with myeloproliferative neoplasms: a large cohort of 183 patients. Eur J Intern Med. 2019;68:71–5.CrossRef Venton G, Turcanu M, Colle J, Thuny F, Chebrek S, Farnault L, et al. Pulmonary hypertension in patients with myeloproliferative neoplasms: a large cohort of 183 patients. Eur J Intern Med. 2019;68:71–5.CrossRef
12.
go back to reference Brabrand M, Hansen K, Laursen C, Larsen TS, Vestergaard H, Abildgaard N. Frequency and etiology of pulmonary hypertension in patients with myeloproliferative neoplasm. Eur J Haematol. 2019;102:227–34.CrossRef Brabrand M, Hansen K, Laursen C, Larsen TS, Vestergaard H, Abildgaard N. Frequency and etiology of pulmonary hypertension in patients with myeloproliferative neoplasm. Eur J Haematol. 2019;102:227–34.CrossRef
13.
go back to reference Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome—negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057–69.CrossRef Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome—negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057–69.CrossRef
14.
go back to reference Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120:5128–33.CrossRef Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120:5128–33.CrossRef
15.
go back to reference Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895–901.CrossRef Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895–901.CrossRef
16.
go back to reference Passamonti F, Cervantes F, Maria A, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115:1703–8.CrossRef Passamonti F, Cervantes F, Maria A, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115:1703–8.CrossRef
17.
go back to reference Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009;113:4829–923.CrossRef Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009;113:4829–923.CrossRef
18.
go back to reference Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, et al. Revised response criteria for myelofibrosis: International Working Group–Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122:1395–8.CrossRef Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, et al. Revised response criteria for myelofibrosis: International Working Group–Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122:1395–8.CrossRef
19.
go back to reference Adir Y, Elia D, Harari S. Pulmonary hypertension in patients with chronic myeloproliferative disorders. Eur Respir Rev. 2015;24:400–10.CrossRef Adir Y, Elia D, Harari S. Pulmonary hypertension in patients with chronic myeloproliferative disorders. Eur Respir Rev. 2015;24:400–10.CrossRef
20.
go back to reference Garcia-Manero G, Schuster SJ, Patrick H, Martinez J. Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases. Am J Hematol. 1999;60:130–5.CrossRef Garcia-Manero G, Schuster SJ, Patrick H, Martinez J. Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases. Am J Hematol. 1999;60:130–5.CrossRef
21.
go back to reference Cortelezzi A, Gritti G, Del Papa N, Pasquini MC, Calori R, Gianelli U, et al. Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status. Leukemia. 2008;22:646–9.CrossRef Cortelezzi A, Gritti G, Del Papa N, Pasquini MC, Calori R, Gianelli U, et al. Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status. Leukemia. 2008;22:646–9.CrossRef
22.
go back to reference Altintas A, Karahan Z, Pasa S, Cil T, Boyraz T, Iltumur K, et al. Pulmonary hypertension in patients with essential thrombocytopenia and reactive thrombocytosis. Leuk Lymphoma. 2007;48:1981–7.CrossRef Altintas A, Karahan Z, Pasa S, Cil T, Boyraz T, Iltumur K, et al. Pulmonary hypertension in patients with essential thrombocytopenia and reactive thrombocytosis. Leuk Lymphoma. 2007;48:1981–7.CrossRef
23.
go back to reference Chebrek S, Aissi K, Frances Y, Mercier C, Farnault L, Sébahoun G, et al. Pulmonary hypertension in patients with chronic myeloproliferative neoplasms. Leuk Lymphoma. 2014;55:223–5.CrossRef Chebrek S, Aissi K, Frances Y, Mercier C, Farnault L, Sébahoun G, et al. Pulmonary hypertension in patients with chronic myeloproliferative neoplasms. Leuk Lymphoma. 2014;55:223–5.CrossRef
24.
go back to reference Mattar M, Morad M, Husseiny N, Ali NH, El Demerdash DM. Correlation between JAK2 allele burden and pulmonary arterial hypertension and hematological parameters in Philadephia negative JAK2 positive myeloproliferative neoplasms: an Egyptian experience. Ann Hematol. 2016;95:1611–6.CrossRef Mattar M, Morad M, Husseiny N, Ali NH, El Demerdash DM. Correlation between JAK2 allele burden and pulmonary arterial hypertension and hematological parameters in Philadephia negative JAK2 positive myeloproliferative neoplasms: an Egyptian experience. Ann Hematol. 2016;95:1611–6.CrossRef
25.
go back to reference Fraidenburg D, Machado R. Pulmonary hypertension associated with thalassemia syndromes. Ann NY Acad Sci. 2016;1368:127–39.CrossRef Fraidenburg D, Machado R. Pulmonary hypertension associated with thalassemia syndromes. Ann NY Acad Sci. 2016;1368:127–39.CrossRef
26.
go back to reference Derchi G, Galanello R, Bina P, Cappellini MD, Piga A, Lai ME, et al. Prevalence and risk factors for pulmonary arterial hypertension in a large group of β-thalassemia patients using right heart catheterization: a Webthal study. Circulation. 2014;129:338–45.CrossRef Derchi G, Galanello R, Bina P, Cappellini MD, Piga A, Lai ME, et al. Prevalence and risk factors for pulmonary arterial hypertension in a large group of β-thalassemia patients using right heart catheterization: a Webthal study. Circulation. 2014;129:338–45.CrossRef
27.
go back to reference Moreira EM, Gall H, Leening MJG, Lahousse L, Loth DW, Krijthe BP, et al. Prevalence of pulmonary hypertension in the general population: the Rotterdam study. PLoS ONE. 2015;10:e0130072.CrossRef Moreira EM, Gall H, Leening MJG, Lahousse L, Loth DW, Krijthe BP, et al. Prevalence of pulmonary hypertension in the general population: the Rotterdam study. PLoS ONE. 2015;10:e0130072.CrossRef
28.
go back to reference Berra G, Noble S, Soccal P, Beghetti M, Lador F. Pulmonary hypertension in the elderly: a different disease? Breathe. 2016;12:43–9.CrossRef Berra G, Noble S, Soccal P, Beghetti M, Lador F. Pulmonary hypertension in the elderly: a different disease? Breathe. 2016;12:43–9.CrossRef
29.
go back to reference Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica. 2007;92:135–6.CrossRef Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica. 2007;92:135–6.CrossRef
Metadata
Title
Prevalence and risk factors of high echocardiographic probability of pulmonary hypertension in myeloproliferative neoplasms patients
Authors
Yanika Jindamai
Ekarat Rattarittamrong
Arintaya Phrommintikul
Lalita Yongsmith
Pokpong Piriyakhuntorn
Thanawat Rattanathammethee
Sasinee Hantrakool
Chatree Chai-Adisaksopha
Adisak Tantiworawit
Lalita Norasetthada
Publication date
01-11-2020
Publisher
Springer Singapore
Published in
International Journal of Hematology / Issue 5/2020
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-020-02952-4

Other articles of this Issue 5/2020

International Journal of Hematology 5/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine